Business Description
TME Pharma NV
ISIN : NL0015000YE1
Compare
Compare
Traded in other countries / regions
ALTME.France0N6A.Germany IPO Date
2018-09-10Description
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 540.6 | |||||
| Equity-to-Asset | 0.53 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 59.1 | |||||
| 3-Year EPS without NRI Growth Rate | 64.1 | |||||
| 3-Year FCF Growth Rate | 57.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.09 | |||||
| 9-Day RSI | 45.92 | |||||
| 14-Day RSI | 48.04 | |||||
| 6-1 Month Momentum % | -49.98 | |||||
| 12-1 Month Momentum % | -61.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.11 | |||||
| Quick Ratio | 2.11 | |||||
| Cash Ratio | 1.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -221.6 | |||||
| Shareholder Yield % | -70.79 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1709.46 | |||||
| ROA % | -213.32 | |||||
| ROIC % | -347.94 | |||||
| 3-Year ROIIC % | 30.94 | |||||
| ROC (Joel Greenblatt) % | -5573.63 | |||||
| ROCE % | -1459.64 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.14 | |||||
| Price-to-Tangible-Book | 3.19 | |||||
| EV-to-EBIT | -0.51 | |||||
| EV-to-EBITDA | -0.53 | |||||
| EV-to-FCF | -0.75 | |||||
| Price-to-Net-Current-Asset-Value | 3.19 | |||||
| Price-to-Net-Cash | 4.25 | |||||
| Earnings Yield (Greenblatt) % | -196.68 | |||||
| FCF Yield % | -91.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TME Pharma NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.472 | ||
| Beta | 0.5 | ||
| Volatility % | 80.64 | ||
| 14-Day RSI | 48.04 | ||
| 14-Day ATR (€) | 0.016442 | ||
| 20-Day SMA (€) | 0.12968 | ||
| 12-1 Month Momentum % | -61.89 | ||
| 52-Week Range (€) | 0.0902 - 0.4195 | ||
| Shares Outstanding (Mil) | 42.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TME Pharma NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TME Pharma NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
TME Pharma NV Frequently Asked Questions
What is TME Pharma NV(FRA:0N6A)'s stock price today?
The current price of FRA:0N6A is €0.13. The 52 week high of FRA:0N6A is €0.42 and 52 week low is €0.09.
When is next earnings date of TME Pharma NV(FRA:0N6A)?
The next earnings date of TME Pharma NV(FRA:0N6A) is .
Does TME Pharma NV(FRA:0N6A) pay dividends? If so, how much?
TME Pharma NV(FRA:0N6A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers